Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series
Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment. In this single‐center case series, detection of BRAFV600‐ and...
Gespeichert in:
| Veröffentlicht in: | Pigment cell and melanoma research 2024-11, Vol.37 (6), p.822-830 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 830 |
|---|---|
| container_issue | 6 |
| container_start_page | 822 |
| container_title | Pigment cell and melanoma research |
| container_volume | 37 |
| creator | Dirven, Iris Vounckx, Manon Kessels, Jolien I. Lauwyck, Justine Awada, Gil Vanbinst, Anne‐Marie Neyns, Bart |
| description | Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment. In this single‐center case series, detection of BRAFV600‐ and NRASQ61‐mutant cell‐free tumor DNA (cfDNA) in CSF was evaluated as a complementary diagnostic biomarker. In 12 patients with clinical suspicion of LMM, a retrospective analysis of MRI, CSF cytology and cfDNA analysis on 1 mL of CSF using the Idylla® platform was carried out. Nine patients displayed MRI abnormalities suggesting LMM. CSF analysis identified malignant cells in three patients (including one without MRI abnormalities). BRAFV600‐ or NRASQ61‐mutant cfDNA was detected in CSF of nine patients (eight with and one without MRI abnormalities; all patients with positive CSF cytology). Subsequent follow‐up confirmed LMM in all patients with positive and in one patient with a negative CSF cfDNA analysis (sensitivity 81.8%; specificity 100%). Our findings suggest that analyzing BRAFV600‐ and NRASQ61‐mutant cfDNA in CSF using the Idylla® platform holds promise as a sensitive and specific complementary diagnostic biomarker for LMM, particularly in case of inconsistency between imaging and CSF cytology. The 110‐min analysis can facilitate urgent treatment decisions.
Automated cfDNA analysis on CSF can be used as additional sensitive and specific diagnostic biomarker for leptomeningeal melanoma metastasis, Allowing for reduced lumbar punctures to obtain positive cytology results and quicker treatment decisions. |
| doi_str_mv | 10.1111/pcmr.13186 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3079170352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3079170352</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2466-ae170c4c3bef113daba2eb8b8e8655bf17bd228ce6a5d05bfdf802e76a3c27d73</originalsourceid><addsrcrecordid>eNp9kc1O3DAUha2qqPyUDQ-ALHWDkAbsOIk97EZDW5AGqKoisYts5xoZkjjYiarZdcuOZ-yTcIcBFl3UsuQr3-8ey-cQssfZEcd13Ns2HnHBVfmBbHFZFBOeq5uP77Xkm2Q7pTvGSlZMxSeyKdR0ylRebJHHUxjADj50NDhqoWn-_nlyEYAOYxsiPb2cUd9hI4KJIfW-0w11zehrqhPVtPb6tgtp8JYaH1od7yFSh4MN9ENoofPdLeBIC43usI_FoBNun07ojFqdgCaIHtJnsuF0k2D39dwh19--_pqfTRZX38_ns8XEZnlZTjRwyWxuhQHHuai10RkYZRSosiiM49LUWaYslLqoGV7UTrEMZKmFzWQtxQ45WOv2MTyMkIaq9Wn1cd1BGFMlmJziE6LIEP3yD3oXxogOIMUztF7mL9ThmrJoUIrgqj56dGJZcVatAqpWAVUvASG8_yo5mhbqd_QtEQT4GvjtG1j-R6r6Mb_4uRZ9BsUPnpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3121117452</pqid></control><display><type>article</type><title>Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Dirven, Iris ; Vounckx, Manon ; Kessels, Jolien I. ; Lauwyck, Justine ; Awada, Gil ; Vanbinst, Anne‐Marie ; Neyns, Bart</creator><creatorcontrib>Dirven, Iris ; Vounckx, Manon ; Kessels, Jolien I. ; Lauwyck, Justine ; Awada, Gil ; Vanbinst, Anne‐Marie ; Neyns, Bart</creatorcontrib><description>Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment. In this single‐center case series, detection of BRAFV600‐ and NRASQ61‐mutant cell‐free tumor DNA (cfDNA) in CSF was evaluated as a complementary diagnostic biomarker. In 12 patients with clinical suspicion of LMM, a retrospective analysis of MRI, CSF cytology and cfDNA analysis on 1 mL of CSF using the Idylla® platform was carried out. Nine patients displayed MRI abnormalities suggesting LMM. CSF analysis identified malignant cells in three patients (including one without MRI abnormalities). BRAFV600‐ or NRASQ61‐mutant cfDNA was detected in CSF of nine patients (eight with and one without MRI abnormalities; all patients with positive CSF cytology). Subsequent follow‐up confirmed LMM in all patients with positive and in one patient with a negative CSF cfDNA analysis (sensitivity 81.8%; specificity 100%). Our findings suggest that analyzing BRAFV600‐ and NRASQ61‐mutant cfDNA in CSF using the Idylla® platform holds promise as a sensitive and specific complementary diagnostic biomarker for LMM, particularly in case of inconsistency between imaging and CSF cytology. The 110‐min analysis can facilitate urgent treatment decisions.
Automated cfDNA analysis on CSF can be used as additional sensitive and specific diagnostic biomarker for leptomeningeal melanoma metastasis, Allowing for reduced lumbar punctures to obtain positive cytology results and quicker treatment decisions.</description><identifier>ISSN: 1755-1471</identifier><identifier>ISSN: 1755-148X</identifier><identifier>EISSN: 1755-148X</identifier><identifier>DOI: 10.1111/pcmr.13186</identifier><identifier>PMID: 38990845</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Abnormalities ; Adult ; Aged ; Aged, 80 and over ; biomarker ; Biomarkers ; Biomarkers, Tumor - cerebrospinal fluid ; Biomarkers, Tumor - genetics ; brain metastases ; Cell-Free Nucleic Acids - cerebrospinal fluid ; Cell-Free Nucleic Acids - genetics ; Cellular biology ; cell‐free tumor DNA ; Cerebrospinal fluid ; Circulating Tumor DNA - blood ; Circulating Tumor DNA - cerebrospinal fluid ; Circulating Tumor DNA - genetics ; Cytology ; Deoxyribonucleic acid ; Diagnostic systems ; DNA ; Female ; GTP Phosphohydrolases - genetics ; Humans ; leptomeningeal metastasis ; Magnetic resonance imaging ; Male ; Melanoma ; Melanoma - cerebrospinal fluid ; Melanoma - diagnosis ; Melanoma - genetics ; Melanoma - pathology ; Membrane Proteins - cerebrospinal fluid ; Membrane Proteins - genetics ; Meningeal Neoplasms - cerebrospinal fluid ; Meningeal Neoplasms - diagnosis ; Meningeal Neoplasms - genetics ; Meningeal Neoplasms - pathology ; Meningeal Neoplasms - secondary ; Meninges ; Metastases ; Middle Aged ; Mutants ; Mutation ; Neuroimaging ; Patients ; Proto-Oncogene Proteins B-raf - genetics ; Retrospective Studies ; Sensitivity analysis ; Tumors</subject><ispartof>Pigment cell and melanoma research, 2024-11, Vol.37 (6), p.822-830</ispartof><rights>2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2024 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2466-ae170c4c3bef113daba2eb8b8e8655bf17bd228ce6a5d05bfdf802e76a3c27d73</cites><orcidid>0000-0003-2168-0781</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpcmr.13186$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpcmr.13186$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38990845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dirven, Iris</creatorcontrib><creatorcontrib>Vounckx, Manon</creatorcontrib><creatorcontrib>Kessels, Jolien I.</creatorcontrib><creatorcontrib>Lauwyck, Justine</creatorcontrib><creatorcontrib>Awada, Gil</creatorcontrib><creatorcontrib>Vanbinst, Anne‐Marie</creatorcontrib><creatorcontrib>Neyns, Bart</creatorcontrib><title>Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series</title><title>Pigment cell and melanoma research</title><addtitle>Pigment Cell Melanoma Res</addtitle><description>Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment. In this single‐center case series, detection of BRAFV600‐ and NRASQ61‐mutant cell‐free tumor DNA (cfDNA) in CSF was evaluated as a complementary diagnostic biomarker. In 12 patients with clinical suspicion of LMM, a retrospective analysis of MRI, CSF cytology and cfDNA analysis on 1 mL of CSF using the Idylla® platform was carried out. Nine patients displayed MRI abnormalities suggesting LMM. CSF analysis identified malignant cells in three patients (including one without MRI abnormalities). BRAFV600‐ or NRASQ61‐mutant cfDNA was detected in CSF of nine patients (eight with and one without MRI abnormalities; all patients with positive CSF cytology). Subsequent follow‐up confirmed LMM in all patients with positive and in one patient with a negative CSF cfDNA analysis (sensitivity 81.8%; specificity 100%). Our findings suggest that analyzing BRAFV600‐ and NRASQ61‐mutant cfDNA in CSF using the Idylla® platform holds promise as a sensitive and specific complementary diagnostic biomarker for LMM, particularly in case of inconsistency between imaging and CSF cytology. The 110‐min analysis can facilitate urgent treatment decisions.
Automated cfDNA analysis on CSF can be used as additional sensitive and specific diagnostic biomarker for leptomeningeal melanoma metastasis, Allowing for reduced lumbar punctures to obtain positive cytology results and quicker treatment decisions.</description><subject>Abnormalities</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>biomarker</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - cerebrospinal fluid</subject><subject>Biomarkers, Tumor - genetics</subject><subject>brain metastases</subject><subject>Cell-Free Nucleic Acids - cerebrospinal fluid</subject><subject>Cell-Free Nucleic Acids - genetics</subject><subject>Cellular biology</subject><subject>cell‐free tumor DNA</subject><subject>Cerebrospinal fluid</subject><subject>Circulating Tumor DNA - blood</subject><subject>Circulating Tumor DNA - cerebrospinal fluid</subject><subject>Circulating Tumor DNA - genetics</subject><subject>Cytology</subject><subject>Deoxyribonucleic acid</subject><subject>Diagnostic systems</subject><subject>DNA</subject><subject>Female</subject><subject>GTP Phosphohydrolases - genetics</subject><subject>Humans</subject><subject>leptomeningeal metastasis</subject><subject>Magnetic resonance imaging</subject><subject>Male</subject><subject>Melanoma</subject><subject>Melanoma - cerebrospinal fluid</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - genetics</subject><subject>Melanoma - pathology</subject><subject>Membrane Proteins - cerebrospinal fluid</subject><subject>Membrane Proteins - genetics</subject><subject>Meningeal Neoplasms - cerebrospinal fluid</subject><subject>Meningeal Neoplasms - diagnosis</subject><subject>Meningeal Neoplasms - genetics</subject><subject>Meningeal Neoplasms - pathology</subject><subject>Meningeal Neoplasms - secondary</subject><subject>Meninges</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Mutants</subject><subject>Mutation</subject><subject>Neuroimaging</subject><subject>Patients</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Retrospective Studies</subject><subject>Sensitivity analysis</subject><subject>Tumors</subject><issn>1755-1471</issn><issn>1755-148X</issn><issn>1755-148X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1O3DAUha2qqPyUDQ-ALHWDkAbsOIk97EZDW5AGqKoisYts5xoZkjjYiarZdcuOZ-yTcIcBFl3UsuQr3-8ey-cQssfZEcd13Ns2HnHBVfmBbHFZFBOeq5uP77Xkm2Q7pTvGSlZMxSeyKdR0ylRebJHHUxjADj50NDhqoWn-_nlyEYAOYxsiPb2cUd9hI4KJIfW-0w11zehrqhPVtPb6tgtp8JYaH1od7yFSh4MN9ENoofPdLeBIC43usI_FoBNun07ojFqdgCaIHtJnsuF0k2D39dwh19--_pqfTRZX38_ns8XEZnlZTjRwyWxuhQHHuai10RkYZRSosiiM49LUWaYslLqoGV7UTrEMZKmFzWQtxQ45WOv2MTyMkIaq9Wn1cd1BGFMlmJziE6LIEP3yD3oXxogOIMUztF7mL9ThmrJoUIrgqj56dGJZcVatAqpWAVUvASG8_yo5mhbqd_QtEQT4GvjtG1j-R6r6Mb_4uRZ9BsUPnpA</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Dirven, Iris</creator><creator>Vounckx, Manon</creator><creator>Kessels, Jolien I.</creator><creator>Lauwyck, Justine</creator><creator>Awada, Gil</creator><creator>Vanbinst, Anne‐Marie</creator><creator>Neyns, Bart</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2168-0781</orcidid></search><sort><creationdate>202411</creationdate><title>Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series</title><author>Dirven, Iris ; Vounckx, Manon ; Kessels, Jolien I. ; Lauwyck, Justine ; Awada, Gil ; Vanbinst, Anne‐Marie ; Neyns, Bart</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2466-ae170c4c3bef113daba2eb8b8e8655bf17bd228ce6a5d05bfdf802e76a3c27d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Abnormalities</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>biomarker</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - cerebrospinal fluid</topic><topic>Biomarkers, Tumor - genetics</topic><topic>brain metastases</topic><topic>Cell-Free Nucleic Acids - cerebrospinal fluid</topic><topic>Cell-Free Nucleic Acids - genetics</topic><topic>Cellular biology</topic><topic>cell‐free tumor DNA</topic><topic>Cerebrospinal fluid</topic><topic>Circulating Tumor DNA - blood</topic><topic>Circulating Tumor DNA - cerebrospinal fluid</topic><topic>Circulating Tumor DNA - genetics</topic><topic>Cytology</topic><topic>Deoxyribonucleic acid</topic><topic>Diagnostic systems</topic><topic>DNA</topic><topic>Female</topic><topic>GTP Phosphohydrolases - genetics</topic><topic>Humans</topic><topic>leptomeningeal metastasis</topic><topic>Magnetic resonance imaging</topic><topic>Male</topic><topic>Melanoma</topic><topic>Melanoma - cerebrospinal fluid</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - genetics</topic><topic>Melanoma - pathology</topic><topic>Membrane Proteins - cerebrospinal fluid</topic><topic>Membrane Proteins - genetics</topic><topic>Meningeal Neoplasms - cerebrospinal fluid</topic><topic>Meningeal Neoplasms - diagnosis</topic><topic>Meningeal Neoplasms - genetics</topic><topic>Meningeal Neoplasms - pathology</topic><topic>Meningeal Neoplasms - secondary</topic><topic>Meninges</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Mutants</topic><topic>Mutation</topic><topic>Neuroimaging</topic><topic>Patients</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Retrospective Studies</topic><topic>Sensitivity analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dirven, Iris</creatorcontrib><creatorcontrib>Vounckx, Manon</creatorcontrib><creatorcontrib>Kessels, Jolien I.</creatorcontrib><creatorcontrib>Lauwyck, Justine</creatorcontrib><creatorcontrib>Awada, Gil</creatorcontrib><creatorcontrib>Vanbinst, Anne‐Marie</creatorcontrib><creatorcontrib>Neyns, Bart</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pigment cell and melanoma research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dirven, Iris</au><au>Vounckx, Manon</au><au>Kessels, Jolien I.</au><au>Lauwyck, Justine</au><au>Awada, Gil</au><au>Vanbinst, Anne‐Marie</au><au>Neyns, Bart</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series</atitle><jtitle>Pigment cell and melanoma research</jtitle><addtitle>Pigment Cell Melanoma Res</addtitle><date>2024-11</date><risdate>2024</risdate><volume>37</volume><issue>6</issue><spage>822</spage><epage>830</epage><pages>822-830</pages><issn>1755-1471</issn><issn>1755-148X</issn><eissn>1755-148X</eissn><abstract>Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment. In this single‐center case series, detection of BRAFV600‐ and NRASQ61‐mutant cell‐free tumor DNA (cfDNA) in CSF was evaluated as a complementary diagnostic biomarker. In 12 patients with clinical suspicion of LMM, a retrospective analysis of MRI, CSF cytology and cfDNA analysis on 1 mL of CSF using the Idylla® platform was carried out. Nine patients displayed MRI abnormalities suggesting LMM. CSF analysis identified malignant cells in three patients (including one without MRI abnormalities). BRAFV600‐ or NRASQ61‐mutant cfDNA was detected in CSF of nine patients (eight with and one without MRI abnormalities; all patients with positive CSF cytology). Subsequent follow‐up confirmed LMM in all patients with positive and in one patient with a negative CSF cfDNA analysis (sensitivity 81.8%; specificity 100%). Our findings suggest that analyzing BRAFV600‐ and NRASQ61‐mutant cfDNA in CSF using the Idylla® platform holds promise as a sensitive and specific complementary diagnostic biomarker for LMM, particularly in case of inconsistency between imaging and CSF cytology. The 110‐min analysis can facilitate urgent treatment decisions.
Automated cfDNA analysis on CSF can be used as additional sensitive and specific diagnostic biomarker for leptomeningeal melanoma metastasis, Allowing for reduced lumbar punctures to obtain positive cytology results and quicker treatment decisions.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38990845</pmid><doi>10.1111/pcmr.13186</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2168-0781</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1755-1471 |
| ispartof | Pigment cell and melanoma research, 2024-11, Vol.37 (6), p.822-830 |
| issn | 1755-1471 1755-148X 1755-148X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3079170352 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Abnormalities Adult Aged Aged, 80 and over biomarker Biomarkers Biomarkers, Tumor - cerebrospinal fluid Biomarkers, Tumor - genetics brain metastases Cell-Free Nucleic Acids - cerebrospinal fluid Cell-Free Nucleic Acids - genetics Cellular biology cell‐free tumor DNA Cerebrospinal fluid Circulating Tumor DNA - blood Circulating Tumor DNA - cerebrospinal fluid Circulating Tumor DNA - genetics Cytology Deoxyribonucleic acid Diagnostic systems DNA Female GTP Phosphohydrolases - genetics Humans leptomeningeal metastasis Magnetic resonance imaging Male Melanoma Melanoma - cerebrospinal fluid Melanoma - diagnosis Melanoma - genetics Melanoma - pathology Membrane Proteins - cerebrospinal fluid Membrane Proteins - genetics Meningeal Neoplasms - cerebrospinal fluid Meningeal Neoplasms - diagnosis Meningeal Neoplasms - genetics Meningeal Neoplasms - pathology Meningeal Neoplasms - secondary Meninges Metastases Middle Aged Mutants Mutation Neuroimaging Patients Proto-Oncogene Proteins B-raf - genetics Retrospective Studies Sensitivity analysis Tumors |
| title | Detection of cell‐free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T02%3A36%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20of%20cell%E2%80%90free%20tumor%20DNA%20in%20cerebrospinal%20fluid%20as%20a%20diagnostic%20biomarker%20for%20leptomeningeal%20melanoma%20metastasis:%20A%20case%20series&rft.jtitle=Pigment%20cell%20and%20melanoma%20research&rft.au=Dirven,%20Iris&rft.date=2024-11&rft.volume=37&rft.issue=6&rft.spage=822&rft.epage=830&rft.pages=822-830&rft.issn=1755-1471&rft.eissn=1755-148X&rft_id=info:doi/10.1111/pcmr.13186&rft_dat=%3Cproquest_cross%3E3079170352%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3121117452&rft_id=info:pmid/38990845&rfr_iscdi=true |